Dossier assessment
Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment-naive adults with metastatic non-small cell lung cancer with activating EGFR mutations
EGFR mutations Del19 or L858R: hint of lesser benefit versus appropriate comparator therapy; other EGFR mutations: added benefit not proven.
Project details
- Project no.
- A20-13
- Commission
- Commission awarded on 14.02.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Ramucirumab - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed